# A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy

> **NCT01328951** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 643 (actual)

## Conditions studied

- Non-Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Placebo
- **DRUG:** Erlotinib
- **DRUG:** Second-Line Chemotherapy

## Key facts

- **NCT ID:** NCT01328951
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2015-12
- **Final completion:** 2016-01
- **Target enrollment:** 643 (ACTUAL)
- **Last updated:** 2016-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01328951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01328951, "A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01328951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*